Loprinzi, Charles L. http://orcid.org/0000-0001-8044-5752
Novotny, Paul
Ruddy, Kathryn J.
Jatoi, Aminah
Le-Rademacher, Jennifer
Ehlers, Shawna L.
Cathcart-Rake, Elizabeth
Lee, Minji
Article History
Received: 24 February 2023
Accepted: 20 July 2023
First Online: 27 July 2023
Declarations
:
: There was no ethical committee review as this is a commentary-type manuscript, as opposed to a clinical trial. Mayo ethical committee does not require approval for the current manuscript.
: This is not applicable for this review manuscript.
: Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics; personal fees from Asahi Kasei/Veloxis; personal fees from Metys Pharmaceuticals; personal fees from OnQuality; personal fees from Mitsubishi Tanabe; personal fees from NKMax, personal fees from Novartis; personal fees from HengRui; personal fees from Nuro Bio, personal fees from Osmol Therapeutics, Inc.; personal fees from Grunenthal; personal fees from Genentech outside the submitted work; personal fees from Bexion outside the submitted work; personal fees from Emmes Company outside the submitted work; personal fees from Pfizer outside the submitted work; and personal fees from Toray outside the submitted work. He also reports royalties from UpToDate. Dr. Ruddy reports royalties from UpToDate.